Dupuytrens

Millions struck by a disease that leaves them with an almost useless 'claw hand' could soon benefit from a drug that halts the condition before it can do any damage.It also means many could avoid risky surgery – which can damage sensitive…

Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early stage Dupuytren's disease. "This phase 2b trial represents…